" class="no-js "lang="en-US"> European Healthtech Mindgram Closes €7 Million Seed Round and Begins Its European Expansion - Medtech Alert
Thursday, February 29, 2024

European Healthtech Mindgram Closes €7 Million Seed Round and Begins Its European Expansion

Mindgram, the European B2B platform providing integrated support for employees in the well-being sphere, has closed one of the biggest seed funding rounds in Europe for its sector. The startup is launching in Spain as the beginning of its international expansion, indicating Portugal and other LATAM markets as their next steps. Mindgram is an all-in-one solution for companies aiming to grant their team holistic emotional and mental well-being support, to build their resilience and drive performance. The online platform addresses the full spectrum of employee needs in the mental sphere – providing on one hand tools to manage stress, burnout, communication difficulties, family problems, treat depression, etc. and supporting the development of emotional and cognitive competencies on the other.  The service is available 24 hours a day, 7 days a week.  The company already has an established presence in Poland, with a pool of recognizable corporate clients including among others – Pfizer, UNUM, DB Schenker, Packhelp, and Mary Kay.

Mindgram co-founder and CEO, Jakub Zieliński, has commented, “Well-being of the team is nowadays a fundamental pillar for the development of any company. It’s the new KPI of performance. With the mental distress epidemic we are facing in Europe and across the world, it’s not enough to react to incidents. Prevention is key to fighting anxiety and building engaged teams in the long term. Taking care of the employees’ emotions and well-being not only creates a better work environment. It helps you build a clear EVP, benefits the productivity of your team, reduces turnover and ultimately supports the company growth.”

The seed round closed by Mindgram is one the largest of this kind for a mental health company and one of the largest for any Poland founded startup. “We are delighted to be able to help more companies across the world with the funds for further development. I would like to thank the investors for their trust and the whole team for their work. This round reinforces our vision of helping to build mentally strong and resilient organizations” – says Jakub Zieliński.

Guillaume Fournier, Partner at Credo Ventures said: “The COVID-19 crisis and the war in Ukraine have accelerated public awareness of mental health issues in the workplace. While the US leads the way with employer-provided access to care and services, the rest of the world lags far behind. Mindgram has blown us away with their pace and quality of execution to remedy this issue, providing employers with a one-stop-shop solution adapted to patient journeys. The unmatched levels of traction among their customers’ employee base is a testimony of the appetite for and effectiveness of what they have built”.

Credo Ventures has invested in outstanding technology founders coming from the CEE region at an early stage since 2010. Over the years the fund has backed such companies as Uipath, Productboard, Deepnote, and many more.

Aurel Pasztor, Partner at Portfolion Capital Partners commented: “Demand for mental health and wellbeing-related services has grown continuously since the pandemic started. Mindgram provides a holistic set of services on a clean B2B platform that is rapidly adopted by enterprises. We believe there is a lot of need for this service in the region and Mindgram’s team has proved to be very strong in execution. We are fully committed to helping them grow in Europe and beyond.”

Marcin Kurek, Managing Partner at Market One Capital comments: “Decision to invest in Mindgram at pre-seed stage was the fastest ever made at Market One Capital. It took us only 5 business days from the first meeting to issue a Term Sheet.  Stellar Team with a great track record, huge market, and booming demand for mental health services were the fundamentals of our conviction. Less than a year later it occurred to us that we were totally right to back those amazing founders. Great business traction and fast product development led to one of the biggest seed rounds in CEE ever, where we as MOC naturally took part as well”.

The money raised from the round will be used for expansion on new markets and further development of the platform, including implementation of Data-Driven Care strategy, in liaison with Nunatak Capital. The VC led by a team of data scientists with extensive academic and business experience will support Mindgram in areas of Big Data, Data Analytics & AI. “We are excited to support Mindgram with our data-science expertise on its way to developing data-driven mental care solutions. Mindgram will offer its customers new features as hyper-personalization, company well-being data monitoring, text-based therapy automation, and digital phenotyping to build its unique value proposition” – says Piotr Ciżkowicz, Managing Partner of Nunatak Capital and Associated Professor at Warsaw School of Economics.

“We see this area as our competitive advantage and differentiation from other players” – says Jakub Zieliński.

Upon the launch, in Spain, the company grants access to 600 local psychotherapists. The Mindgram local team is already growing rapidly, it includes a number of psychologists, trainers, and coaches as well as HR market experts. The company intends to initially hire up to 50 employees in Spain and will work from offices in Madrid and Barcelona.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more